Interleukin-2 gene therapy (VCL-IM01)

Drug Profile

Interleukin-2 gene therapy (VCL-IM01)

Alternative Names: Electroporation-delivered DNA immunotherapy against metastatic melanoma - Inovio/Vical; IL-2 plasmid DNA/lipid complex (Leuvectin); IL-2-based DNA vaccine - Vical; IL-2/EP - Vical; Interleukin-2 gene therapy - Vical; VCL-1M01; VCL-IM01

Latest Information Update: 20 May 2010

Price : $50

At a glance

  • Originator Vical
  • Developer Inovio Pharmaceuticals; Vical
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Gene transference; Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer

Highest Development Phases

  • Discontinued Malignant melanoma; Prostate cancer; Renal cancer

Most Recent Events

  • 18 Dec 2008 Final efficacy and adverse events data from a phase I trial in Metastatic melanoma presented at the DNA Vaccines 2008 Conference (DNA Vaccines-2008)
  • 11 Jun 2007 Interim results from a phase I clinical trial in patients with Metastatic melanoma added to the adverse events and Cancer therapeutic trials sections
  • 27 Jul 2005 Phase-I clinical trials in Metastatic melanoma in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top